Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Summary

The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.

Eligibility

Inclusion Criteria (all criteria must apply):

* Cytologic or histologic proof of adenocarcinoma of the pancreas.
* Localized, potentially resectable tumors.
* Greater or equal to 18 years of age.
* ECOG performance status of 0 or 1.
* Adequate hematologic, renal and hepatic function as defined by:
* ANC greater or equal to 1,500 cells/mm3
* Platelets greater or equal to 100,000 cells/mm3
* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
* Serum creatinine ≤ 2 x ULN • ALT ≤ 5 x ULN
* AST ≤ 5 x ULN
* No history of prior therapy for pancreatic cancer.
* No history of active infection requiring IV antibiotics at the start of study treatment
* Non-pregnant and non-breast-feeding.

Exclusion Criteria:

* Patient has borderline resectable or metastatic disease.
* History of malignancy in the last 5 years other than in situ cancer or basal or squamous cell skin cancer or malignancies cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.
* Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.

Conditions3

Locations1 site

Browse More Trials